P
GILD icon

&Partners’s Gilead Sciences GILD Stock Holding History

&Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8M Buy
403,145
+18,877
+5% +$2.49M 0.21% 97
2026
Q1 		$53.6M Buy
384,268
+31,484
+9% +$4.41M 0.26% 79
2025
Q4 		$43.3M Buy
352,784
+49,405
+16% +$6M 0.23% 89
2025
Q3 		$33.6M Buy
303,379
+29,789
+11% +$3.39M 0.22% 102
2025
Q2 		$30.3M Buy
273,590
+171,989
+169% +$18.3M 0.23% 97
2025
Q1 		$11.4M Buy
101,601
+3,272
+3% +$338K 0.12% 163
2024
Q4 		$8.99M Buy
98,329
+37,315
+61% +$3.36M 0.11% 188
2024
Q3 		$5.12M Buy
61,014
+35,279
+137% +$2.69M 0.1% 201
2024
Q2 		$1.76M Buy
25,735
+21,511
+509% +$1.44M 0.08% 232
2024
Q1 		$309K Buy
+4,224
New +$325K 0.04% 358
2020
Q2 		– Sell
-2,700
Closed -$202K – 143
2020
Q1 		$202K Buy
+2,700
New +$187K 0.31% 100

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

&Partners's GILD Position: Q2 2026 in Review

&Partners increased its Gilead Sciences (GILD) stake by 4.9% in Q2 2026, buying an estimated $2.49M and bringing the position to 403,145 shares worth $50.8M. The position accounts for 0.21% of the portfolio, ranked #97.

&Partners first reported a position in GILD in Q1 2020 and has held it in 11 quarters since. The position peaked at $53.6M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • &Partners held 403,145 shares of Gilead Sciences worth $50.8M as of Q2 2026.
  • &Partners bought 18,877 Gilead Sciences shares in Q2 2026, an estimated $2.49M.
  • Gilead Sciences made up 0.21% of &Partners's portfolio in Q2 2026, its #97 holding.
  • &Partners first reported a position in Gilead Sciences in Q1 2020 and has held it in 11 quarters since.
  • &Partners's Gilead Sciences position peaked at $53.6M in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.